Pharnext (France) a preclinical-stage biopharmaceutical company focused on treatment for Charcot-Marie-Tooth and other neuromuscular diseases, closed a $3.5M Series B financing. Participants include Parinvest Capital, La Financiere Gaspard and Truffle Capital
Thanx for your patience as we catch-up.